Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants

Vaccine

Volumn 31, Issue S4, 2013, Pages

  Madhi, Shabir A ^a,b,c   Dangor, Ziyaad ^b,c   Heath, Paul T ^d   Schrag, Stephanie ^e   Izu, Alaine ^b,c   Sobanjo ter Meulen, Ajoke ^f   Dull, Peter M ^f  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e Ctr for Dis Control and Prevention   (United States)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Conjugate vaccine; Group B streptococcus; Pregnant women

Indexed keywords

GROUP B STREPTOCOCCUS POLYSACCHARIDE PROTEIN CONJUGATE VACCINE; MATERNAL ANTIBODY; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; DRUG SAFETY; FOLLOW UP; GESTATIONAL AGE; GROUP B STREPTOCOCCAL INFECTION; HEALTH CARE QUALITY; IMMUNOGENICITY; INCIDENCE; PASSIVE IMMUNIZATION; PERINATAL ASPHYXIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND TRIMESTER PREGNANCY; SEROTYPE; STREPTOCOCCUS AGALACTIAE; STUDY DESIGN;

CONJUGATE VACCINE; GROUP B STREPTOCOCCUS; PREGNANT WOMEN;

CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84882946596     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.029     Document Type: Review

References (49)

1. Liu L., Johnson H.L., Cousens S., Perin J., Scott S., Lawn J.E., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379(9832):2151-2161.
2. Dagnew A.F., Cunnington M.C., Dube Q., Edwards M.S., French N., Heyderman R.S., et al. Variation in reported neonatal group B streptococcal disease incidence in developing countries. Clin Infect Dis 2012, 55(1):91-102.
3. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379(9815):547-556.
4. Cutland C.L., Schrag S.J., Zell E.R., Kuwanda L., Buchmann E., Velaphi S.C., et al. Maternal HIV infection and vertical transmission of pathogenic bacteria. Pediatrics 2012, 130(3):e581-e590.
5. Gray K.J., Bennett S.L., French N., Phiri A.J., Graham S.M. Invasive group B streptococcal infection in infants, Malawi. Emerg Infect Dis 2007, 13(2):223-229.
6. Berkley J.A., Lowe B.S., Mwangi I., Williams T., Bauni E., Mwarumba S., et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005, 352(1):39-47.
7. Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz L.B., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000, 342(1):15-20.
8. Schrag S.J., Verani J.R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 2012.
9. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010, 59(RR-10):1-36.
10. Lopez Sastre J.B., Fernandez Colomer B., Coto Cotallo G.D., Ramos Aparicio A. Trends in the epidemiology of neonatal sepsis of vertical transmission in the era of group B streptococcal prevention. Acta Paediatr 2005, 94(4):451-457.
11. Koenig J.M., Keenan W.J. Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis. Pediatr Clin North Am 2009, 56(3):689-708.
12. Weston E.J., Pondo T., Lewis M.M., Martell-Cleary P., Morin C., Jewell B., et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011, 30(11):937-941.
13. Montagu D., Yamey G., Visconti A., Harding A., Yoong J. Where do poor women in developing countries give birth? A multi-country analysis of demographic and health survey data. PLoS One 2011, 6(2). p. e17155.
14. World Health Organisation. www.who.int/immunization_monitoring/diseases/.../en/index.html. Accessed 5 Jan 2013.
15. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359(15):1555-1564.
16. Steinhoff M.C., Omer S.B., Roy E., El Arifeen S., Raqib R., Dodd C., et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. Can Med Assoc J 2012, 184(6):645-653.
17. Steinhoff M.C., Omer S.B. A review of fetal and infant protection associated with antenatal influenza immunization. Am J Obstet Gynecol 2012, 207(Suppl. 3):S21-S27.
18. Omer S.B., Goodman D., Steinhoff M.C., Rochat R., Klugman K.P., Stoll B.J., et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011, 8(5). e1000441.
19. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996, 98(10):2308-2314.
20. Heath P.T. An update on vaccination against group B streptococcus. Exp Rev Vacc 2011, 10(5):685-694.
21. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003, 188(1):66-73.
22. Heath P.T., Balfour G., Weisner A.M., Efstratiou A., Lamagni T.L., Tighe H., et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004, 363(9405):292-294.
23. Christensen K.K., Christensen P., Duc G., Hoger P., Kind C., Matsunaga T., et al. Correlation between serum antibody-levels against group B streptococci and gestational age in newborns. Eur J Pediatr 1984, 142(2):86-88.
24. Madhi S.A., Radebe K., Crewe-Brown H., Frasch C.E., Arakere G., Mokhachane M., et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 2003, 23(1):15-23.
25. Rivera L.S., Feris J., Ip M., Saha S., Adrian P., Boudville I., et al. Multi-center Study of the Burden of Invasive Neonatal and Early Infant Group B Streptococcal Disease. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012.
26. Kuehn B.M. ACIP. Give pertussis vaccine during every pregnancy. JAMA 2012, 308(19). p. 1960.
27. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet. Gynecol. 2012, 119(3):690-691.
28. Schuchat A., Zywicki S.S., Dinsmoor M.J., Mercer B., Romaguera J., O'Sullivan M.J., et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics 2000, 105(1 Pt 1):21-26.
29. Heath P.T., Balfour G.F., Tighe H., Verlander N.Q., Lamagni T.L., Efstratiou A., et al. Group B streptococcal disease in infants: a case control study. Arch Dis Child 2009, 94(9):674-680.
30. Thaver D., Ali S.A., Zaidi A.K. Antimicrobial resistance among neonatal pathogens in developing countries. Pediatr Infect Dis J 2009, 28(Suppl. 1):S19-S21.
31. Angell M. The ethics of clinical research in the Third World. N Engl J Med 1997, 337(12):847-849.
32. Aaby P., Babiker A., Darbyshire J., Nunn A., Barreto S., Alonso P., et al. Ethics of HIV trials. Lancet 1997, 350(9090). p. 1546.
33. Strategic Advisory Group of Experts (SAGE) on Immunization: Accessed 5 Jan 2013. http://wwwwhoint/entity/influenza/vaccines/SAGE_information/en/indexhtml%202012.
34. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(3):401-409.
35. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B112-B116.
36. Baker C.J., Kasper D.L. Immunological investigation of infants with septicemia or meningitis due to group B Streptococcus. J Infect Dis 1977, 136(104):S98-S104.
37. Boyer K.M., Papierniak C.K., Gadzala C.A., Parvin J.D., Gotoff S.P. Transplacental passage of IgG antibody to group B streptococcus serotype Ia. J Pediatr 1984, 104(4):618-620.
38. Edwards M.S., Fuselier P.A., Rench M.A., Kasper D.L., Baker C.J. Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay. Infect Immun 1984, 44(2):257-261.
39. Davies H.D., Adair C., McGeer A., Ma D., Robertson S., Mucenski M., et al. Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J Infect Dis 2001, 184(3):285-291.
40. Lachenauer C.S., Baker C.J., Baron M.J., Kasper D.L., Gravekamp C., Madoff L.C. Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. J Infect Dis 2002, 185(3):368-374.
41. Baker C.J., Kasper D.L., Tager I., Paredes A., Alpert S., McCormack W.M., et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest 1977, 59(5):810-818.
42. Baker C.J., Edwards M.S., Kasper D.L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981, 68(4):544-549.
43. Suara R.O., Adegbola R.A., Mulholland E.K., Greenwood B.M., Baker C.J. Seroprevalence of antibodies to group B streptococcal polysaccharides in Gambian mothers and their newborns. J Natl Med Assoc 1998, 90(2):109-114.
44. Lin F.Y., Philips J.B., Azimi P.H., Weisman L.E., Clark P., Rhoads G.G., et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001, 184(8):1022-1028.
45. Lin F.Y., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., Rhoads G.G., et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004, 190(5):928-934.
46. Klegerman M.E., Boyer K.M., Papierniak C.K., Gotoff S.P. Estimation of the protective level of human IgG antibody to the type-specific polysaccharide of group B Streptococcus type Ia. J Infect Dis 1983, 148(4):648-655.
47. Feldman R.G., Breukels M.A., David S., Rijkers G.T. Properties of human anti-group B streptococcal type III capsular IgG antibody. Clin Immunol Immunopathol 1998, 86(2):161-169.
48. Cutland C.L., Madhi S.A., Zell E.R., Kuwanda L., Laque M., Groome M., et al. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet 2009, 374(9705):1909-1916.
49. Madzivhandila M., Adrian P.V., Cutland C.L., Kuwanda L., Schrag S.J., Madhi S.A. Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads. PLoS One 2011, 6(3):e17861.